Viva Biotech Holdings

Hong Kong-listed CRDMO (1873.HK) providing integrated end-to-end drug discovery and manufacturing services including peptide development and GMP manufacturing. PPO department includes 50+ PhDs specializing in peptides, proteins, and oligonucleotides. CDMO subsidiary Langhua Pharma offers CMC development, peptide API GMP scale-up, and global regulatory filing support.

Viva Biotech Holdings is listed as a CDMO in the peptide supply chain, serving Asia markets from China (Shanghai). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. Verification is supported by 1 independent source, including documentation review and cross-referencing against public records. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.